Wiley, Proteomics: Clinical Applications, 3-4(9), p. 437-443, 2015
Full text: Download
SRM: Selected Reaction MonitoringTargeted personalized treatment options have become a major hope of clinical (e.g. cancer) research within the past years [1]. Success stories like herceptin [2] in breast cancer and BRAFV600E inhibitors [3] in melanoma have kindled the quest to identify novel biomarkers for diagnosis, patient stratification and personalised treatment options.This article is protected by copyright. All rights reserved